The Latin America, Middle East and Africa Bronchodilators Market would witness market growth of 7.8% CAGR during the forecast period (2022-2028).
One of the significant parameters responsible for the growth of the bronchodilator market is the decreasing functionality of lungs along with aging. These physical and cognitive changes generally make normal breathing difficult in the elderly. Also, the old adult population is more vulnerable to respiratory disorders like chronic obstructive pulmonary disease (COPD) and asthma.
The rising prevalence of respiratory diseases and the increased levels of air pollution, coupled with the surge in tobacco smokers, are boosting the incidence of infectious diseases among the elderly population, which significantly contribute toward the risk of developing lung disorders and collectively drive the growth of the market.
Anticholinergics are bronchodilators primarily utilized for treating COPD (chronic obstructive pulmonary disease, like emphysema) and asthma. Atrovent treats COPD and can be utilized off-label to treat asthma flares. Patients can get it as a nebulizer solution and inhaler. Revefenacin (Yupelri) is the new medication used regularly to aid those with COPD to breathe easier. Long-acting is taken once a day with a nebulizer.
In Saudi Arabia, the prevalence of the chronic obstructive pulmonary disease is 4.2% among the general population and 14.2% among smokers. In 2014, respiratory disease combined represented the fifth leading cause of death in Saudi Arabia, according to the Ministry of Health (MoH). Around 3388 people with respiratory diseases died in 2014 compared to 1892 in 2010. The rising prevalence of non-communicable diseases or chronic obstructive pulmonary disease will increase the need for medications like bronchodilators, thus, surging the market expansion in the region.
The Brazil market dominated the LAMEA Bronchodilators Market by Country in 2021; thereby, achieving a market value of $388.7 million by 2028. The Argentina market is showcasing a CAGR of 8.4% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 7.5% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Bronchodilators Market is Projected to reach USD 27 Billion by 2028, at a CAGR of 3.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Route of Administration
By Disease
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 